Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$31.27 ▼ -1.34
(-4.11%)
MKT CAP: $1.61B • VOL: 1.29M
52W L $28 52W H $41
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$26
MEDIAN
$35
MEAN
$36
HIGH
$43
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE IMCR TAPE
IMCR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $37.84 | $35.96 | 2025-02-14 | $28.46 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $39.40 | $36.90 | 2025-02-06 | $29.39 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $35.65 | $34.40 | 2025-01-29 | $30.02 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $31.90 | — | 2025-01-17 | $30.64 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $27.52 | $29.71 | 2025-01-09 | $27.83 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $37.21 | $32.52 | 2024-12-18 | $27.20 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $30.33 | $31.58 | 2024-12-04 | $29.08 | -4.3% | 48% | C |